Mast cell tumor clinical trial for dogs.

CALIFORNIA
Study: Evaluation of Previcox (firocoxib) on the severity and duration of radiation induced skin
reactions in dogs
Location: University of California Veterinary Hospital Davis, CA
Phone:     (530) 752-1393, ext 431
www.vmth.ucdavis.edu/vmth/services/oncology/oncology.html

Eligibility: Canine patients with Cancer on the trunk or extremities undergoing Radiation Therapy: Soft Tissue Sarcomas
or Mast Cell Tumors. Microscopic disease requiring full course (3Gyx16) radiation therapy for a tumor on the trunk or
extremities, the canine patient must be able to tolerate both forms of antiinflammatory drug (for randomization), Must be
able to return to UC Davis for 2 and 6 week recheck visits.

Summary: The purpose of this study is to assess the affect of the NSAID Previcox (firocoxib) and Prednisone on the
development, severity and duration of radiation induced skin reactions in dogs. Treated dogs will be compared to
animals receiving no therapy during radiation. Additionally, radiation induced skin reactions will be described. Side
Effects of the antiinflammatory drugs will be monitored.

Requirements and incentives: Owner will be asked to complete a questionnaire weekly for the first 6 weeks. Once the
patient is enrolled, the study pays for the cost of the Previcox. For more information regarding this clinical trial, please
contact our Clinical Trials Coordinator at 530.752.0125.

Study: Evaluation of Denamarin in preventing liver toxicity during CCNU chemotherapy treatment in
dogs
Location: University of California Veterinary Hospital Davis, CA
Phone:     (530) 752-1393, ext 431
www.vmth.ucdavis.edu/vmth/services/oncology/oncology.html

Eligibility: To qualify for this study, the canine patient must have a confirmed diagnosis of Lymphoma, Mast Cell Tumor or
Hystiocytic Sarcoma. Patients beginning CCNU as chemotherapy with normal blood ALT levels and are not on any other
anti-oxidants, are eligible for the study.

Summary: Dogs with cancer that will be receiving CCNU as part of their chemotherapy protocol will be asked to
participate in a randomized study. CCNU is a commonly used chemotherapeutic drug used to treat dogs with lymphoma,
mast cell tumors, histiocytic sarcoma, and other cancers. CCNU is known to be hepatoxic and most dogs receiving the
drug will experience some changes in blood liver values, although clinical signs of liver failure are rare. In some cases,
these changes require treatment adjustments and, occasionally, treatment may be discontinued to avoid severe liver
damage. Denamarin is a combination of two nutraceuticals, S-adenosylmethionine and Marin, both of which have proven
hepatoprotective effects. The purpose of this study is to determine whether Denamarin prevents blood liver value
elevations in dogs with cancer that are being treated with CCNU. Dogs will be randomized to start Denamarin treatment
at the time CCNU is first prescribed.

Requirements and incentives: The owner is responsible for the cost of the initial tests and most treatment costs to
insure eligibility to participate. Additionally, the client will be required to fill out a questionnaire on their pets progress
once a week. Once the patient is enrolled, the study pays for the cost of regular bloodwork to evaluate liver health at
each visit and for the DenomarinTM that will be provided at no cost to the owner. For more information regarding this
clinical trial, please contact our Clinical Trials Coordinator at 530.752.0125.

CONNECTICUT
Study: Canine Mast Cell Tumor
Location: Veterinary Oncology&Hematology Clinic, Norwalk, CT
Phone:     203-838-6626
www.oncovet.com/vohc-clinic.htm

Summary: Open to dogs with a recurrent or nonresectable Grade II or III Mast Cell Tumor, without metastasis or lymph
node involvement. The study provides novel oral medication that will be given once daily at home. Diagnostics required
prior to enrollment include chest x-rays, abdominal ultrasound, bloodwork and urinalysis. If metastasis is confirmed, the
client is responsible for the cost of diagnostics, if no evidence of metastasis, the study may cover all costs associated
with diagnostics and treatment. In addition, a small biopsy sample is required to confirm tumor Grade prior to enrollment.

TEXAS
Study: Canine Mast Cell Tumor
Location: Gulf Coast Veterinary Specialists, South Houston, TX
Phone:      713-692-1111
http://www.gcvs.com/oncology/gcvo_trials.htm

Summary: Dogs with recurrent or nonresectable grade 2 or 3 mast cell tumor(s) without nodal or visceral metastasis are
eligible for this trial. The pet owner is responsible for a nominal initial examination fee. If eligible, additional procedures
for trial entry (complete laboratory, tumor biopsy, diagnostic imaging), scheduled visits, and all treatments are at no cost
to the pet owner during this 6 month clinical trial. Dogs will be treated with a novel oral medication that may reverse the
genetic aberrations in mast cells of dogs that lead to tumor development.